Filing Details

Accession Number:
0001640455-23-000053
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-04-06 16:37:50
Reporting Period:
2023-04-04
Accepted Time:
2023-04-06 16:37:50
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1640455 Jounce Therapeutics Inc. JNCE () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1242935 /Ca/ Richard Murray C/O Jounce Therapeutics, Inc.
780 Memorial Drive
Cambridge MA 02139
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2023-04-04 39,228 $1.85 188,779 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Footnotes
  1. Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. The automatic sale instructions for the sell-to-cover were intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Securities Exchange Act of 1934, as amended, and to be interpreted to comply with the requirements of Rule 10b5-1(c), and these instructions were given on September 17, 2019.